Bellerophon Therapeutics Inc

Bellerophon Therapeutics — Investor Presentation (January 2021)

32 slides from Bellerophon Therapeutics's investor presentation, Jan 11, 2021

  1. Slide 1: 2021 Company Presentation, January 2021

    2021 Company Presentation I Company Presentation I January 2021 Bellerophon Therapeutics

  2. Slide 2: Forward Looking Statements

    2021 Company Presentation I 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future fina

  3. Slide 3: Bellerophon Therapeutics (BLPH) Company Profile

    2021 Company Presentation I • Focused on developing inhaled nitric oxide (iNO) based therapies for management of serious cardiopulmonary and infectious diseases • Portable, lightweight delivery system (INOpulse®) allows for chronic home use • Simplified regulatory approval pathway via existing nitri

  4. Slide 4: Management Team and Chairman

    2021 Company Presentation I Jonathan Peacock Chairman 10 years experience as CFO at Amgen and Novartis Pharma Fabian Tenenbaum Chief Executive Officer 15 years of executive-level experience in finance, BD and operations Wassim Fares, M.D., MSc Chief Medical Officer 20 years experience in clinical re

  5. Slide 5: Development Pipeline

    2021 Company Presentation I PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 NDA Key Milestones fILD Fibrotic Interstitial Lung Disease at risk of Pulmonary Hypertension Phase 2 Hemodynamic Trial Completed Positive results in Feb 2020 Phase 2 Chronic Trial Complete Positive Cohort 1 results in Jan 2019 Positive

  6. Slide 6: INOpulse Delivery System Overview

    2021 Company Presentation I Nitric Oxide Portable pulsatile iNO delivery system Novel drug-device combination therapy with multiple mechanisms of action Well-established vasodilator approved for acute treatment of persistent pulmonary hypertension in hospitals Proprietary algorithm ensures accurate

  7. Slide 7: INOpulse Delivery System: Lightweight, Portable and User Friendly

    2021 Company Presentation I 7 INOpulse Delivery System Lightweight, Portable and User Friendly Alarm Cannula Key & ConnectorDrug & Battery Indicators Power Oxygen Sources Easy engagement with drug cartridge Intuitive and simple user interface Tri-lumen cannula allows direct connection with oxygen Li

  8. Slide 8: INOpulse Provides a Unique and Differentiating Mechanism of Action

    2021 Company Presentation I 8 INOpulse Provides a Unique and Differentiating Mechanism of Action Baseline Hypoxic pulmonary vasoconstriction prevents oxygen desaturation Systemic Vasodilators Systemic vasodilators can reverse hypoxic vasoconstriction leading to ventilation/perfusion (V/Q) mismatch a

  9. Slide 9: Fibrotic Interstitial Lung Disease (fILD): A Significant Unmet Medical Need

    2021 Company Presentation I 9 Fibrotic Interstitial Lung Disease (fILD) A Significant Unmet Medical Need Normal IPF • Fibrotic Interstitial Lung Disease (fILD) is a broad category of diffuse lung diseases characterized by variable amounts of inflammation and fibrosis • Idiopathic Pulmonary Fibrosis

  10. Slide 10: Pulmonary Hypertension associated with fILD Significantly Reduces Survival

    2021 Company Presentation I 10 Pulmonary Hypertension (PH) associated with fILD Significantly Reduces Survival Pulmonary Hypertension as Predictor of Survival in IPF • Approximately 40% of IPF patients exhibit symptoms of pulmonary hypertension at rest • Prognosis and survival are significantly wors

  11. Slide 11: fILD Market Opportunity in the US

    2021 Company Presentation I Source: LEK report (2018) 11 fILD Market Opportunity in the US 0 500 1,000 1,500 2,000 2,500 3,000 2017 2022E IPF branded drug sales (2017) Millions of USD ~3,000 Estimated Penetration: ~24,000 in US Based on: LTOT penetration of 70-75% Physician adoption rate of 35-60% P

  12. Slide 12: Phase 2: INOpulse Demonstrates Targeted Vasodilation in fILD

    2021 Company Presentation I Targeted Vasodilation Ventilation/Vasodilation Matching 12 Phase 2: INOpulse Demonstrates Targeted Vasodilation in fILD Acute Phase Data Showed Immediate Benefit of INOpulse on Vasodilation and Hemodynamics • Significant correlation between ventilation and vasodilation, d

  13. Slide 13: Phase 2: INOpulse Demonstrates Acute Hemodynamic Benefit in fILD

    2021 Company Presentation I 13 Phase 2: INOpulse Demonstrates Acute Hemodynamic Benefit in fILD Clinically and statistically meaningful cardiopulmonary improvement on iNO30 w/ cont. benefit on dose escalation Pulmonary hemodynamics measured via right heart catheterization at baseline and following e

  14. Slide 14: Continuous Monitoring of Physical Activity

    2021 Company Presentation I Continuous Monitoring of Physical Activity Study participant wears actigraphy monitor on non- dominant arm Monitor continuously measures movement in acceleration units Movement is Categorized into Activity Intensity Levels Activity Intensity Example activities Sedentary (

  15. Slide 15: Phase 2 Results Suggest Clinically Meaningful Benefit in MVPA

    2021 Company Presentation I 15 Phase 2 Results Suggest Clinically Meaningful Benefit in MVPA (moderate to vigorous physical activity) • Study participants on INOpulse (iNO30 and iNO45) maintain activity levels while study participants on placebo deteriorate across activity parameters • Study partici

  16. Slide 16: Phase 2 Patient Demographics

    2021 Company Presentation I 16 Cohort 1 (n=41) iNO 30 n=23 Placebo n=18 Age – years (mean, SD) 68.6 (6.45) 65.8 (13.73) Male (n, %) 16 (69.6%) 13 (72.2%) Intermediate to High Probability of PH (n, %) 15 (65.2%) 14 (77.8%) Baseline DLCO – % predicted (mean, SD) 30.7 (11.4) 30.4 (10.2) Baseline FVC –

  17. Slide 17: Longitudinal Benefit of iNO in MVPA and Overall Activity

    2021 Company Presentation I 17 Analysis based on MMRM model to estimate therapeutic benefit through treatment period based on all available data as planned for pivotal Phase 3 study 20% benefit after 4 months of treatment p=0.02 Overall ActivityMVPA 7% benefit after 4 months of treatment Longitudina

  18. Slide 18: Benefit Observed in MVPA at Month 4 on iNO45

    2021 Company Presentation I 18 Study participants on INOpulse maintain activity levels while study participants on placebo deteriorate Study participants on INOpulse demonstrate 7.5 min/day (~10%) benefit over placebo after 2 months of treatment p=0.02 MVPA Month 4MVPA Month 2 Benefit increases to 1

  19. Slide 19: Continued Benefit for Participants on Open Label Extension

    2021 Company Presentation I 19 Continued Benefit for Study Participants on Open Label Extension (OLE) Study participants transitioning from placebo to active demonstrate trend reversal from deterioration to maintenance • MVPA = moderate to vigorous physical activity • Change is based on Cohort 1 stu

  20. Slide 20: UCSD Shortness of Breath Questionnaire Indicates Benefit in Dyspnea

    2021 Company Presentation I 20 • Placebo corrected improvement of 4 points • Measures shortness of breath while study participants perform daily physical activity Increased score indicative of worsening UCSD SOBQ iNO45: UCSD Shortness of Breath Questionnaire (SOBQ) Indicates Benefit in Dyspnea • Dat

  21. Slide 21: St. George's Respiratory Questionnaire Indicates QOL Benefit

    2021 Company Presentation I 21 • Placebo corrected improvement of 6 points • Measures psychological and social impact of the disease • Placebo corrected improvement of 6 points • Measures disturbances to study participants’ daily physical activity • Placebo corrected improvement of 4 points • Measur

  22. Slide 22: Phase 2 Safety Summary

    2021 Company Presentation I 22 Phase 2 Safety Summary INOpulse was well-tolerated in Cohort 1 and Cohort 2 Cohort 1 (8 weeks) iNO 30 n=23 Placebo n=18 Study participants with Adverse Events 19 (82.6%) 15 (83.3%) Study participants with Serious Adverse Events 2 (8.7%) 2 (11.1%) Total Serious Adverse

  23. Slide 23: Phase 2 Results Allow Immediate Transition into Pivotal Phase 3 Trial

    2021 Company Presentation I PHASE 2 PHASE 3 23 Double-blind placebo-controlled study will assess study participants with fibrotic interstitial lung disease at risk of associated pulmonary hypertension • Phase 2 Complete: Cohorts 1 and 2 suggest improvement in MVPA supported by other activity paramet

  24. Slide 24: An Orphan Unmet Medical Need: PH associated with Sarcoidosis

    2021 Company Presentation I An Orphan Unmet Medical Need Pulmonary Hypertension associated with Sarcoidosis (PH-Sarc) 24 Patients with associated PH have significantly reduced survival 1-year survival 3-year survival 5-year survival PH-Sarc 84% 74% 59% Sarc 100% 96% 96% Sarcoidosis is characterized

  25. Slide 25: INOpulse MoA has the Potential to Provide Benefit to PH-Sarc Patients

    2021 Company Presentation I 25 INOpulse MoA has the Potential to Provide Benefit to PH-Sarc Patients Inhaled nitric oxide has been shown to improve hemodynamics and exercise capacity in PH-Sarc Preston et al., Chest, 2001 Chronic Benefit on Exercise Capacity Acute Hemodynamic Benefit on iNO Paramete

  26. Slide 26: PH-COPD Represents Large Unmet Medical Need

    2021 Company Presentation I Andersen KH et al. Prevalence, Predictors and Survival in Pulmonary Hypertension Related to End-stage Chronic Obstructive Pulmonary Disease. Journal of Heart and Lung Transplantation 2012; 31: 373-380. 26 • Typically associated with smoking or exposure to other pollutants

  27. Slide 27: INOpulse Improves Hemodynamics and Exercise Capacity in PH-COPD Patients

    2021 Company Presentation I Haijan et al., Int J of COPD, 2016 27 p<0.05* p<0.05* p<0.05* Change in 6MWD sPAP *Statistically significant compared to baseline Study participants completing 4 weeks on iNO 30 demonstrated: • Statistically significant increase in 6MWD at 2 weeks and 4 weeks (+50.7m) • S

  28. Slide 28: INOpulse for the Treatment of COVID-19

    2021 Company Presentation I 28 INOpulse for the Treatment of COVID-19 FDA granted emergency expanded access for pulsatile inhaled nitric oxide for treating COVID-19 • 180 patients treated at 18 hospitals across the US under emergency expanded access • Preliminary data demonstrated recovery rate of 7

  29. Slide 29: INOpulse Intellectual Property Protection

    2021 Company Presentation I 29 INOpulse Intellectual Property Protection Orphan Drug designation for IPF provides exclusivity for 7 years (US) and up to 10 years (EU) Patent Status Expiration Description Method of NO administration US/EU: Issued Other Territories: Issued/Pending Jan 2027 Covers cons

  30. Slide 30: Financial Summary

    2021 Company Presentation I 1. As of September 30, 2020 30 Financial Summary Amount (in millions) Cash and Cash Equivalents $54.0 (1) Restricted Cash $0.4(1) Debt $0(1) Fully Diluted Shares Outstanding 12.2

  31. Slide 31: Investment Highlights Summary

    2021 Company Presentation I Established iNO Therapeutic Benefit • Approved for acute treatment of persistent pulmonary hypertension in neonates • Positive results from multiple Phase 2 studies support INOpulse MoA and benefit Advanced Clinical Stage Product INOpulse technology focused on several lar

  32. Slide 32: Investor Contacts

    2021 Company Presentation I Investor Contacts Fabian Tenenbaum Chief Executive Officer BTInvestorRelations@bellerophon.com Brian Ritchie LifeSci Advisors britchie@lifesciadvisors.com 212-915-2578

Bellerophon Therapeutics — Investor Presentation (January 2021) on 6ix